通过便利远程医疗整合丙型肝炎与阿片类药物使用障碍护理:一项随机试验
这项前瞻性、阶梯楔形整群随机临床试验在纽约州12个阿片类药物治疗项目中比较了整合式便利远程医疗与院外肝病专科转诊对丙型肝炎治愈的影响。结果显示,远程医疗组意向性治愈率为90.3%(262/290),转诊组为39.4%(123/312),估计对数比值比为2.9(95%CI 2.0-3.5;P<.001),且治愈者中非法药物使用显著下降,再感染极少。
要点
- 便利远程医疗组丙型肝炎意向性治愈率90.3%,显著高于转诊组的39.4%(对数比值比2.9;95%CI 2.0-3.5;P<.001)。
- 远程医疗组治疗启动率92.4%(268/290),转诊组为40.4%(126/312)。
- 治愈者中非法药物使用显著下降,再感染13例,丙型肝炎再感染发生率为2.5/100人年。
核心结论
- 阿片类药物治疗项目整合的便利远程医疗相比院外转诊显著提高了丙型肝炎治愈率,参与者满意度高;治愈者中非法药物使用显著下降,再感染极少。
研究设计与样本
- 前瞻性、阶梯楔形整群随机临床试验,纳入纽约州12个阿片类药物治疗项目的丙型肝炎感染参与者(n=602),于2017年3月1日至2020年2月29日入组,数据分析时间为2022年12月1日至2023年9月1日。
- 干预为通过便利远程医疗整合入阿片类药物治疗项目的肝病专科共同管理丙型肝炎直接抗病毒治疗(n=290),对照为标准院外肝病专科转诊(n=312);12个项目起始均为院外转诊,每9个月随机选择4个站点过渡至便利远程医疗,分3个步骤,参与者无交叉。
- 参与者完成2年随访以评估再感染;纳入标准要求阿片类药物治疗入组6个月且丙型肝炎药物有保险覆盖;采用广义线性混合效应模型检验干预效果,调整时间、聚类和效应修饰,进行基于个体的意向性分析。
主要发现
- 602名参与者中,男性369名(61.3%);296名(49.2%)为美洲印第安人或阿拉斯加原住民、亚裔、黑人或非裔美国人、多种族或其他(即未选择种族类别,种族数据按美国国立卫生研究院5个标准类别收集);306名(50.8%)为白人。
- 远程医疗组入组时平均(标准差)年龄为47.1(13.1)岁,转诊组为48.9(12.8)岁。
- 远程医疗组290名参与者中268名(92.4%)启动治疗,转诊组312名中126名(40.4%)启动治疗。
- 意向性治愈率远程医疗组为90.3%(262/290),转诊组为39.4%(123/312),研究组效应估计对数比值比为2.9(95%CI 2.0-3.5;P<.001),无效应修饰。
- 观察到的治愈率远程医疗组为246/290(84.8%),转诊组为106/312(34.0%);亚组效应不显著,包括纤维化分期、城市或农村居住地、心理健康(焦虑或抑郁)共病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Facilitated telemedicine may promote hepatitis C virus elimination by mitigating geographic and temporal barriers. OBJECTIVE: To compare sustained virologic responses for hepatitis C virus among persons with opioid use disorder treated through facilitated telemedicine integrated into opioid treatment programs compared with off-site hepatitis specialist referral. DESIGN, SETTING, AND PARTICIPANTS: Prospective, cluster randomized clinical trial using a stepped wedge design. Twelve programs throughout New York State included hepatitis C-infected participants (n = 602) enrolled between March 1, 2017, and February 29, 2020. Data were analyzed from December 1, 2022, through September 1, 2023. INTERVENTION: Hepatitis C treatment with direct-acting antivirals through comanagement with a hepatitis specialist either through facilitated telemedicine integrated into opioid treatment programs (n = 290) or standard-of-care off-site referral (n = 312). MAIN OUTCOMES AND MEASURES: The primary outcome was hepatitis C virus cure. Twelve programs began with off-site referral, and every 9 months, 4 randomly selected sites transitioned to facilitated telemedicine during 3 steps without participant crossover. Participants completed 2-year follow-up for reinfection assessment. Inclusion criteria required 6-month enrollment in opioid treatment and insurance coverage of hepatitis C medications. Generalized linear mixed-effects models were used to test for the intervention effect, adjusted for time, clustering, and effect modification in individual-based intention-to-treat analysis. RESULTS: Among 602 participants, 369 were male (61.3%); 296 (49.2%) were American Indian or Alaska Native, Asian, Black or African American, multiracial, or other (ie, no race category was selected, with race data collected according to the 5 standard National Institutes of Health categories); and 306 (50.8%) were White. The mean (SD) age of the enrolled participants in the telemedicine group was 47.1 (13.1) years; that of the referral group was 48.9 (12.8) years. In telemedicine, 268 of 290 participants (92.4%) initiated treatment compared with 126 of 312 participants (40.4%) in referral. Intention-to-treat cure percentages were 90.3% (262 of 290) in telemedicine and 39.4% (123 of 312) in referral, with an estimated logarithmic odds ratio of the study group effect of 2.9 (95% CI, 2.0-3.5; P < .001) with no effect modification. Observed cure percentages were 246 of 290 participants (84.8%) in telemedicine vs 106 of 312 participants (34.0%) in referral. Subgroup effects were not significant, including fibrosis stage, urban or rural participant residence location, or mental health (anxiety or depression) comorbid conditions. Illicit drug use decreased significantly (referral: 95% CI, 1.2-4.8; P = .001; telemedicine: 95% CI, 0.3-1.0; P < .001) among cured participants. Minimal reinfections (n = 13) occurred, with hepatitis C virus reinfection incidence of 2.5 per 100 person-years. Participants in both groups rated health care delivery satisfaction as high or very high. CONCLUSIONS AND RELEVANCE: Opioid treatment program-integrated facilitated telemedicine resulted in significantly higher hepatitis C virus cure rates compared with off-site referral, with high participant satisfaction. Illicit drug use declined significantly among cured participants with minimal reinfections. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02933970.
引用
- Talal AH, Markatou M, Liu A, et al. Integrated Hepatitis C-Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial. JAMA. 2024. PMID: 38568601. doi:10.1001/jama.2024.2452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。